60 results about "Chronic kidney failure" patented technology

The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.

The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising a phosphate binder and another pharmaceutically active ingredient. The other pharmaceutically active ingredient is selected from a group consisting of antihypertensives, calcitrol, vitamin D analogues, lipid restriction products, potassium salts, treatments for anemia and alkalization compounds.

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein / bone morphogenetic protein (OP / BMP) family within the TGF-β superfamily of proteins.

The invention discloses a Chinese medicinal composition for treating chronic kidney failure. The Chinese medicinal composition comprises the following raw materials in part by weight: 300 to 400 parts of astragalus, 200 to 300 parts of root of red-rooted salvia, 200 to 300 parts of epimedium, 100 to 200 parts of rhubarb, 200 to 250 parts of polygonum multiflorum thunb. (prepared), 100 to 200 parts of Tuckahoe, 200 to 300 parts of Szechuan lovage rhizome, 200 to 300 parts of Chinese angelica and 100 to 200 parts of fiveleaf gynostemma herb. In the Chinese medicinal composition, medicaments with different effects are matched mutually to achieve the effects of tonifying the spleen and kidney and discharging turbidity and eliminating stasis under the synergetic action, and the Chinese medicinal composition for treating chronic kidney failure has high stability and a good treatment effect. The invention also discloses a preparation method for the Chinese medicinal composition, and the medicinal materials are extracted according to different properties to ensure the curative effect.

The invention relates to a traditional Chinese preparation for treating chronic kidney failure and process for preparation, which is a prepared from Ligusticum wallichii, astragalus root, rhubarb horsetails, Chinese angelica root, epimeddium, dried rehmannia root, root of herbaceous peony, oriental water plantain rhizome, poria cocos wolf, pseudo-ginseng as raw material through disintegration, dissolvent extraction, ripening, sterilizing and granulation.

The present invention is directed to the identification of novel targets for therapeutic intervention and prevention of ischemia and reperfusion injury resulting from hypoxia, stroke, heart attack, chronic kidney failure or organ transplantation. In particular, the present invention is directed to the identification of novel targets for the prevention of reperfusion injury following organ transplantation. The present invention is further directed to methods of high-throughput screening for test compounds capable of inhibiting activity of proteins encoded by the novel targets by combining the test compounds and the protein and detecting binding. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit organ damage resulting from reperfusion injury. Methods for determining the prognosis of long term organ survival in a subject having an organ transplant are also described.

An acetic acid- and / or acetate salt-free iron metabolism-improving agent that contains citric acid and / or a citrate salt as electrolytes and also contains another / other electrolyte / electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and / or a substitution fluid. A method for improving internal iron metabolism and a blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing the dialysate and / or the substitution fluid are further provided.

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method. The traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 6-40 parts of rheum officinale, 10-95 parts of astragalus and 5-65 parts of salvia miltiorrhiza by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum creatinine and urea nitrogen and other indexes of rats subjected to hypertensive nephropathy, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to the chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; and pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure.

The invention relates to a medicine for curing chronic renal failure and a production method thereof, which is characterized in that the medicine is calcium-base samoite excluding K+, Na+, Mg2+ and other exchangeable cations. The preparation method includes immersing the samoite in calcium chloride solution and then exchanging ions. After oral administration, toxins in the alimentary tract of patients with chronic renal failure is absorbed by samoite of the medicine and then discharged out of the body along with intestinal peristalsis, thus achieving intestinal hemodialysis. While absorbing and fixing the toxins in the alimentary tract, the calcium-base samoite has no side effect on patients of Na and K restriction without releasing K+, Na+, Mg2+ and other exchangeable cations.

The invention discloses a traditional Chinese medicine composition for treating a chronic renal failure and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following components in percentage by weight: 5%-20% of processed radix aconiti carmichaeli, 5%-20% of poria cocos, 2%-17% of rhizoma atractylodis macrocephalae, 5%-20% of Chinese herbaceous peony, 5%-20% of ginger, 6%-21% of rheum officinale, 18%-33% of scutellaria baicalensis and 12%-27% of salviae miltiorrhizae. The traditional Chinese medicine composition for treating the chronic renal failure disclosed by the invention has a significant effect on treatment of the chronic renal failure caused by the syndrome of qi deficiency (yang) of the spleen and kidneys and exuberance of internal damp turbidity.

The invention provides methods for preventing end stage renal disease (ESRD) in subjects having a disorder associated with chronic kidney failure, such as diabetes or high blood pressure. Also included are markers (miRNAs) that may be used to identify subjects who are at risk of developing ESRD.

The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and / or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and / or treatment.

The invention belongs to a traditional Chinese medicine preparation, in particular relates to a Shenkang injection compound preparation for treating chronic renal failure. The Shenkang injection compound preparation for treating chronic renal failure is prepared from the following bulk pharmaceutical chemicals: 1500g of rheum officinale, 1500g of roots of the red-rooted salvia, 4500g of Astragalus mongholicus and 1500g of red flower. The preparation method comprises the following steps of: after the bulk pharmaceutical chemicals of the rheum officinale and the roots of red-rooted salvia are extracted in the ratio in the formula, carrying out primary ethanol precipitation, removing tan, carrying out secondary ethanol precipitation and water precipitation, carrying out third ethanol precipitation, and carrying out secondary water precipitation to remove pyrogen and sterilize; then, extracting the red flower and the Astragalus mongholicus in the ratio in the formula, carrying out primary ethanol precipitation and water precipitation, and carrying out secondary ethanol precipitation and water precipitation to remove pyrogen and sterilize; and finally, combining the two groups of liquid medicine, diluting, carrying out ultrafiltration and fine filtering, and sterilizing to obtain the Shenkang injection compound preparation. The Shenkang injection compound preparation has the advantages of precision in regulating the original ratio, high effectiveness, smaller side effect, high acting speed and high bioavailability. In addition, the product quality and the production efficiency are further improved, and energy consumption is reduced.

The present invention relates to a medicine for treating chronic renal failure. The chronic renal failure is the final result of various kidney diseases, but without effective western medicine in clinic yet, and dialysis therapy and renal transplantation price are expensive and not suitable for early and middle patients. The medicine whole formula of the present invention both activates and tonifies, consideration to right and evil, nourishing and releasing integrated, leading nourishing not stagnating evil, releasing not injuring right, can not only delay chronic renal failure course, but also improve or eliminate clinical symptoms, having good curative effect, lower cost characteristic. The present invention concretely is with radix astragali, poria, hedyotis diffusa, serissa foetida, pyrola calliantha, ligusticum chuanxiong, morinda officinalis how, centella asiatica, prepared rhubarb and etc. traditional Chinese medicine to prepare into compound preparation. The present invention also relates to the medicine preparation method. As pharmacological experiment shows the present invention can obviously decrease adenine causing chronic renal failure rat and nephrectomy causing chronic renal failure rat kidney function Crea and BUN value, the present invention can also obviously increase water load rat urinary volume.

The present invention provides one kind of Chinese medicine for treating chronic kidney function failure is prepared with Chinese medicinal materials, including ginseng, astragalus root, white atractylodes rhizome, Chuanxiong rhizome, leech, etc. The medicine has high curative effect, can improve clinical symptoms, reduce urea nitrogen in blood, lower creatinine level, reduce exhausted urine protein, protect kidney function, promote the synthesis of plasma protein, raise plasma protein density, improve body's nutrient state and produce many other positive effects. It is safe clinically and low in production cost.

The invention relates to a Chinese medicinal suppositoria for removing crux, strengthening the body resistance, and removing blood stasis, prepred of the sixteen Chinese drugs: Turmeric Root-tuber, Chinese Angelica, Szechuan Lovage Rhizome, Red Paeony Root, Medicinal Cyathula Root, Common Burreed Tuber, Zedoary, Rehmannia Root, Peach Seed, safflower, Danshen, Turtle Shell, Tortoise Shell, Akebia Stem, Weeping Forsythiae Capsule, and Honeysuckle Flower by dipping, decocting, eliminating impurities by alcoholic sediment, recovering alcohol and concentrating, melt-mixing with substrate and cooling in a mould. And its beneficial effects: providing a meidicine in suppositoria for curing chronic kidney failure, liver fibrosis, liver tumors, gynaecologic pelvic inflammation, muscular tumors of uterus and tumescence of prostate and it has characters of high effective concentration at the affected parts, low toxicity and side effect and high safety.

The invention relates to a traditional Chinese medicine decoction for treating a chronic renal failure and a preparation method of the traditional Chinese medicine decoction. The traditional Chinese medicine decoction is mainly prepared from the following raw materials in parts by weight: 10-20 parts of codonopsis pilosula, 4-9 parts of serissa serissoide, 8-16 parts of poria cocos, 2-6 parts of cassia twig, 10-16 parts of hedysarum polybotrys, 9-16 parts of coix seeds, 5-10 parts of eucommia ulmoides, 6-12 parts of folium ilicis cornutae, 7-15 parts of astragatus complanatus, 3-9 parts of honey-fried licorice roots, 2-7 parts of flavoniodes, 3-7 parts of gecko, 2-6 parts of fruits of belleric terminalia and 4-10 parts of seabuckthorn. The traditional Chinese medicine decoction disclosed by the invention has a significant treatment effect on the chronic renal failure, and is reasonable in compatibility and unique in composition; and a plurality of medicines work together to reach the efficacies of protecting kidney qi, nourishing the liver and kidneys, invigorating the spleen, supplementing qi, tonifying yin and yang, removing blood stasis and turbidity, warming the middle warmer and harmonizing the stomach, and is very suitable for patients with the chronic renal failure for taking.

The invention relates to a new blood concentrated haemodialysis solution which relates to the medical field. The solution is prepared from materials by weight parts as follows: 950-1010 parts of sodium chloride, 15-25 parts of potassium chloride, 45-55 parts of calcium chloride, 15-25 parts of magnesium chloride and 550-650 parts of sodium bicarbonate. The new blood concentrated haemodialysis solution is added into the normal blood concentrated haemodialysis solution. The new blood concentrated haemodialysis solution is suitable for acute / chronic kidney failure and drug poisoning patient to process haemodialysis treatment that mainly solves problem of 'harden' in manufacturing concentrated haemodialysis solution process, at the same time increases storing capability of concentrated haemodialysis solution, and solves medical personnel inconvenient in preparing the concentrated haemodialysis solution.

The invention provides a calcitriol liquid hard capsule, a method for preparing the same and application of the calcitriol liquid hard capsule. Every 1000 calcitriol liquid hard capsules comprise 0.25-0.5 mg of calcitriol, 140-170 g of oil-based matrixes and 25-40 mg of antioxidants. The method includes mixing the antioxidants and the oil-based matrixes with one another to obtain first mixtures; stirring and dissolving the first mixtures and then adding the calcitriol into the first mixtures to obtain second mixtures; continuing to stir and dissolve the second mixtures and then vacuumizing and degassing the second mixtures; filling hard capsule shells with the mixtures to obtain the calcitriol liquid hard capsule. The calcitriol liquid hard capsule, the method and the application have the advantages that the calcitriol liquid hard capsule can be effectively applied to treating post-menopause and senile osteoporosis, chronic renal failure and the like; the content uniformity of the calcitriol liquid hard capsule which is a medicine can be improved, the calcitriol liquid hard capsule is good in stability, long in quality guarantee period, high in bioavailability, low in cost and convenient to administer, and accordingly the calcitriol liquid hard capsule, the method and the application have obvious merits.

The invention discloses a capsule for treating a chronic kidney failure syndrome, and belongs to the field of traditional Chinese medicines. The effective constituents of the capsule comprise the following raw materials in parts by weight: 50-65 parts of white paeony root, 45-60 parts of perilla leaf, 42-58 parts of astragalus mongholicus, 38-54 parts of raw rhubarb, 34-50 parts of fructus forsythia, 30-46 parts of acorus calamus, 28-44 parts of lophatherum gracile, 25-40 parts of radix aconiti lateralis preparata, 22-26 parts of oriental wormwood, 18-22 parts of Sichuan fritillary bulb, 15-28 parts of herba leonuri, 12-25 parts of melon seed, 10-22 parts of blackberry lily, 8-18 parts of akebiaquinata, 5-15 parts of radix cyathulae and 3-12 parts of mirabilite powder. According to the invention, the raw materials complement each other, and the capsule is prepared by scientifically mixing the Chinese herbal medicines with the effects of warming the kidney, benefiting the spleen, descending the turbid, regulating the middle warmer, dredging water passage, tonifying the spleen and kidney, dredging the organs, descending the turbid, and promoting diuresis to remove toxic materials, is specially used for treating kidney and spleen-yang deficiency, turbid accumulation, spleen and kidney-yang deficiency, and water retention and toxin predominance, has a very good treatment effect for various complications of the chronic kidney failure syndrome, and can effectively prolong the survival time of a uremia patient and improve the life quality of the patient.

Disclosing a promoter of the protease MDTS9, which is induced by TGF-β, which is involved in the metabolism of extracellular matrix, and in which the expression of the gene thereof is elevated in renal failure model animals, which promoter is useful as a tool for screening an agent for treating and / or preventing chronic renal failure, as well as a method for screening an agent for treating and / or preventing chronic renal failure by selecting an inhibitor of the promoter.

This invention relates to a medicine for chronic renal failure and its preparation method, and belongs to the technology field of preparing medicine for treating chronic renal failure. The medicine is characterized in comprising the active constituent of F-Glycocalyx which is the valid target of ecklonia kurome and is protein polysaccharides containing sulfate group extracted from ecklonia kurome. the preparation method of F-Glycocalyx comprise (1) selecting, (2) soaking and cleaning, (3) pulverizing, (4) extracting with water, (5) precipitating with alcohol of low concentration, (6)precipitating with alcohol of high concentration, and (7) purifying to obtain purified product, drying, and packaging. The inventive medicine can effectively inhibit malignant tumor viral, improve immunity with no toxicity and adverse side effect, no untoward reaction and low cost.

The present invention relates to compounds useful in the prevention or treatment of various disorders such as acute or chronic renal failure, for impairments of biliary function, for respiratory impairments such as snoring or sleep apneas or for stroke, and pharmaceutical compositions comprising them. More specifically, the compounds of the present invention comprises substituted 1-amino-4-phenyl-dihydroisoquinolines and their derivatives of formula I:Wherein the substituents R1-R11 are more specifically defined hereinbelow. The claimed compounds of the present invention also include their pharmaceutically acceptable salts and trifluoroacetates thereof as well as methods for their preparation and pharmaceutical delivery systems thereof.

The invention relates to a traditional Chinese medicine composition for treatment of chronic kidney failure and a preparation method, a preparation and use thereof, and belongs to the field of clinical treatment of traditional Chinese medicines. The traditional Chinese medicine composition for treatment of chronic kidney failure includes the following four groups of raw materials by weight: an A group selected form 10-25 parts of torrefied rhubarb and / or raw rhubarb; a B group selected form 11-18 parts of salvia miltiorrhiza and / or cortex moutan; a C group selected form 11-18 parts of red peony root and / or cortex moutan; and a D group including 10-14 parts of Chinese angelica, 25-50 parts of raw bone fossil of big mammals, 25-50 parts of raw oysters and 10-20 parts of dandelion. The traditional Chinese medicine composition used in treatment can improve clinical symptoms, reduces serum creatinine, increases endogenous creatinine clearance rate, increases the content of hemoglobin, achieve the curative effect in the treatment of chronic renal failure and complications thereof, delays the progression of the chronic renal failure, and protects the residual renal function, delays dialysis of patients, improves the survival rate and life quality of the patients, reduces medical expenses, reduces family and society burden, and is worthy of popularization and application.

The invention relates to a traditional Chinese medicine composition for treating chronic kidney failure. The composition is composed of the following components by weight: 25 to 35 grams of semen cuscutae, 13 to 17 grams of raspberry, 13 to 17 grams of hemsleya panlongqi, 13 to 17 grams of ligustrum lucidum, 13 to 17 grams of zingiber kawagoii, 13 to 17 grams of spatholobus stem, 18 to 22 grams of prepared rehmannia root, 8 to 12 grams of cistanche, 10 to 14 grams of Chinese angelica, 13 to 17 grams of red sage root, 15 to 25 grams of coix seed, 10 to 14 grams of rhizoma alismatis, 13 to 17 grams of ginseng fruit, 10 to 14 grams of polygonatum odoratum, and 8 to 12 grams of rheum officinale.

The present invention relates to treatment of chronic kidney diseases and particularly discloses kidney-protecting enema liquid effectively treating the chronic kidney diseases. The kidney-protectingenema liquid consists of the following raw materials as active ingredients in parts by weight: 25-36 parts of Chinese rhubarb, 23-34 parts of radix astragali, 16-27 parts of dandelions, 17-25 parts ofcalcined oysters, 18-26 parts of radix salviae miltiorrhizae and 15-24 parts of motherwort. A clinical curative effect comparing total effective stability rate after treatment is 70%, indicating thatthe kidney-protecting enema liquid can effectively alleviate clinical symptoms of chronic kidney failure and is worthy of promotion clinically.

A Chinese medicine for treating chronic renal failure is prepared from more than 10 Chinese- medicinal materials including astragalus root, notoginseng, epimedium, ground beetle, etc.

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and its preparation method and use. The traditional Chinese medicine composition is prepared from the raw material medicines of rheum officinale, astragalus and safflower with a weight ratio of 3-45:9-85:3-65 by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum creatinine and urea nitrogen and other indexes of rats subjected to hypertensive nephropathy, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; and pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure.

The invention relates to a pharmaceutical composition for chronic renal failure and a preparation method thereof. The pharmaceutical composition is prepared from deer blood crystals, poria cocos, dendrobium nobile and rhizoma atractylodis macrocephalae. The preparation method comprises the steps that the poria cocos, the rhizoma atractylodis macrocephalae and the dendrobium nobile are taken and decocted twice with water, after decoction liquid is concentrated, the deer blood crystals and auxiliary materials are added, and a preparation is prepared. The pharmaceutical composition has remarkable effects in the aspects of protecting the renal function and delaying the chronic renal failure.